New sophisticated molecular imaging modalities with multiparametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) using 18F-fluoro-deoxy-glucose (FDG), radiolabeled choline, and alternative radioligands, such as gastrin-releasing peptide receptor (GRPR)-targeting ligand and prostate-specific membrane antigen (PSMA)-targeting ligand, are currently investigated for all aspects of PC, including diagnosis and localization, staging, active surveillance, prognosis, and monitoring recurrence [1]. The gene discussed is GRPR; the disease is pachyonychia congenita.